Safety study of HDP-101 for relapsed myeloma patients
Part of Blood & lymphatic, Cancer, Heart & circulation, Immune system & allergy clinical trials.
This early-phase trial tests whether HDP-101 is safe and can potentially help adults with multiple myeloma that has come back or didn’t respond to standard treatments. It focuses on people who have already tried key myeloma medicines and still have measurable disease.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You’re 18 or older.
- Your overall health is good enough to do daily activities (performance status 0–2).
- You have active multiple myeloma that has relapsed or is not responding.
- You’ve had treatment(s) that included an immunomodulator, a proteasome inhibitor, and an anti-CD38 medicine, and you were either resistant or couldn’t tolerate standard options.
- You either already had a stem cell transplant (SCT) or can’t have one.
- Your kidney, liver, and other organs work well enough for treatment (details checked in the study).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new treatment called OL-101 for people whose multiple myeloma has come back or stopped responding to at least three prior treatments, including a proteasome inhibitor, an immunomodulatory drug, and an anti-CD38 antibody. It aims to see if OL-101 can help control the disease.
This trial tests a combination of study drugs as the first treatment for newly diagnosed multiple myeloma, followed by maintenance based on your risk and response. It aims to improve outcomes while allowing some patients to postpone or avoid a stem cell transplant.
This study tests a new drug called CM336 (a bispecific antibody) combined with standard care for people with high-risk multiple myeloma that came back quickly after first treatment. The goal is to see if it helps control the disease better.
This Phase 1/2 study tests AZD0120 in people with multiple myeloma that has come back or is not responding to treatment. It may help by targeting the myeloma cells after you’ve already tried several standard therapies.
This trial tests a new drug called HDP-101 in patients with multiple myeloma that has come back or stopped responding to previous treatments. The study aims to find the safest and most effective dose and to see if this drug can help control the cancer.
This trial tests a new treatment combination for multiple myeloma that has returned or stopped responding to previous therapy and has spread outside the bone marrow. It aims to see if the combination can shrink these tumors and improve outcomes.
Hear when a new Multiple myeloma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.